Literature DB >> 1093670

The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.

C E Blackard.   

Abstract

The Veterans' Administration Cooperative Urological Research Group has conducted three consecutive randomized clinical trials of various treatments for all stages of prostatic carcinoma. Thus far, a total of 3774 patients have been entered into these three main studies. The first study showed that early endocrine treatment of patients with advanced prostatic cancer did not increase overall survival when compared to initial treatment with placebo alone. Diethylstilbestrol, when given in a dose of 5.0 mg/day, was associated with an increased incidence of cardiovascular deaths. In the second study, diethylstilbestrol given in a dose of 1.0 mg/day has been as effective as the 5.0-mg dose in controlling the prostatic carcinoma but has been associated with a lower incidence of cardiovascular deaths. Patients are still being entered into the third study and it is too early to report the findings in detail.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1093670

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  10 in total

1.  Carcinoma of the prostate.

Authors:  W L Orovan; J E Demaria
Journal:  Can Fam Physician       Date:  1985-06       Impact factor: 3.275

2.  Estrogens in the time of blood-thinners.

Authors:  Yosh Taguchi
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  Prostatic cancer.

Authors:  E P O'Donoghue; G D Chisholm
Journal:  Br Med J       Date:  1976-11-27

4.  Editorial: Prostatic cancer: policies ofr progress.

Authors: 
Journal:  Br Med J       Date:  1976-08-28

5.  Endocrine treatment of prostatic cancer.

Authors:  G Williams
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

6.  High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer.

Authors:  Joshua K Napora; Ryan G Short; Denis C Muller; Olga D Carlson; Juliana O Odetunde; Xiaoqiang Xu; Michael Carducci; Thomas G Travison; Marcello Maggio; Josephine M Egan; Shehzad Basaria
Journal:  J Androl       Date:  2010-08-26

Review 7.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

8.  Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Preetika Sharma; Amy Wisniewski; Milena Braga-Basaria; Xiaoqiang Xu; Mary Yep; Samuel Denmeade; Adrian S Dobs; Theodore DeWeese; Michael Carducci; Shehzad Basaria
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

Review 9.  Hormonal Therapy for Prostate Cancer.

Authors:  Kunal Desai; Jeffrey M McManus; Nima Sharifi
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

Review 10.  Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.

Authors:  Pravien Rajaram; Alyssa Rivera; Kevin Muthima; Nicholas Olveda; Hubert Muchalski; Qiao-Hong Chen
Journal:  Molecules       Date:  2020-05-24       Impact factor: 4.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.